scispace - formally typeset
M

Michael Detmar

Researcher at École Polytechnique Fédérale de Lausanne

Publications -  351
Citations -  43193

Michael Detmar is an academic researcher from École Polytechnique Fédérale de Lausanne. The author has contributed to research in topics: Lymphatic system & Lymphangiogenesis. The author has an hindex of 94, co-authored 334 publications receiving 39086 citations. Previous affiliations of Michael Detmar include Harvard University & Beth Israel Deaconess Medical Center.

Papers
More filters
Journal ArticleDOI

Isolation of human sebaceous glands and cultivation of sebaceous gland-derived cells as an in vitro model.

TL;DR: The cultured cells preserved in vitro morphologic characteristics and differentiation patterns comparable to those described for normal human sebocytes in vivo, with a high rate of viable cells.
Journal ArticleDOI

Lymphatic invasion in cutaneous melanoma is associated with sentinel lymph node metastasis

TL;DR: This data indicates that Sentinel lymph node metastasis is a major determinant for staging, prognostication and clinical management of patients with cutaneous melanoma and the role of lymphatic vs. vascular invasion for SLN spread remains unclear.
Journal ArticleDOI

Ultraviolet B-Induced Skin Angiogenesis Is Associated with a Switch in the Balance of Vascular Endothelial Growth Factor and Thrombospondin-1 Expression

TL;DR: The results demonstrate that acute UVB irradiation leads to a shift toward a proangiogenic environment and they suggest that the balance between VEGF and TSP-1 plays a critical role in the control of angiogenesis and vascular regression induced by acute UV B irradiation.
Journal ArticleDOI

Lymphatic vessels: new targets for the treatment of inflammatory diseases

TL;DR: Surprisingly, activation of lymphatic vessel function by delivery of vascular endothelial growth factor-C exerts anti-inflammatory effects in several models of cutaneous and joint inflammation.
Journal ArticleDOI

Inhibition of Chronic and Acute Skin Inflammation by Treatment with a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor

TL;DR: Results demonstrate for the first time that VEGF receptor tyrosine-kinase inhibitors might be used to treat patients with inflammatory skin disorders such as psoriasis.